A Reflection on Blood Cancer Awareness Month: Patient Spotlight

First Immunosequencing–Based Diagnostic Cleared by FDA

Preview of clonoSEQ Mrd Report

clonoSEQ receives FDA clearance for the detection and monitoring of measurable residual disease (MRD) in patients with multiple myeloma and acute lymphoblastic leukemia.